IBDEI3J5 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2789,0)
 ;;=SUBSTANCE DISORDERS^35^256
 ;;^UTILITY(U,$J,358.4,2790,0)
 ;;=VARICOSE VEINS^36^256
 ;;^UTILITY(U,$J,358.4,2791,0)
 ;;=WOMEN'S HEALTH^37^256
 ;;^UTILITY(U,$J,358.4,2792,0)
 ;;=WOUNDS-INITIAL ENCOUNTER^38^256
 ;;^UTILITY(U,$J,358.4,2793,0)
 ;;=COMA^7^256
 ;;^UTILITY(U,$J,358.4,2794,0)
 ;;=CAUSES OF INJURY^6^256
 ;;^UTILITY(U,$J,358.4,2795,0)
 ;;=DEMENTIA^8^256
 ;;^UTILITY(U,$J,358.4,2796,0)
 ;;=LONG TERM CURRENT DRUG THERAPY^24^256
 ;;^UTILITY(U,$J,358.4,2797,0)
 ;;=NEW PATIENT^2^257
 ;;^UTILITY(U,$J,358.4,2798,0)
 ;;=ESTABLISHED PATIENT^1^257
 ;;^UTILITY(U,$J,358.4,2799,0)
 ;;=CONSULTATIONS^3^257
 ;;^UTILITY(U,$J,358.4,2800,0)
 ;;=POST OP VISIT (GLOBAL)^4^257
 ;;^UTILITY(U,$J,358.4,2801,0)
 ;;=PENIS & SCROTUM^7^258
 ;;^UTILITY(U,$J,358.4,2802,0)
 ;;=URINARY TRACT DRAINAGE & IMAGING^9^258
 ;;^UTILITY(U,$J,358.4,2803,0)
 ;;=URODYNAMICS^10^258
 ;;^UTILITY(U,$J,358.4,2804,0)
 ;;=INJ & INTRAVESICAL MEDS^4^258
 ;;^UTILITY(U,$J,358.4,2805,0)
 ;;=CYSTOURETHROSCOPY^1^258
 ;;^UTILITY(U,$J,358.4,2806,0)
 ;;=PROSTATE BIOPSY & IMAGING^8^258
 ;;^UTILITY(U,$J,358.4,2807,0)
 ;;=NURSING PROCEDURES^6^258
 ;;^UTILITY(U,$J,358.4,2808,0)
 ;;=MISCELLANEOUS^5^258
 ;;^UTILITY(U,$J,358.4,2809,0)
 ;;=IMMUNIZATION ADMIN^2^258
 ;;^UTILITY(U,$J,358.4,2810,0)
 ;;=IMMUNIZATIONS^3^258
 ;;^UTILITY(U,$J,358.4,2811,0)
 ;;=BLADDER^3^259
 ;;^UTILITY(U,$J,358.4,2812,0)
 ;;=BENIGN NEOPLASIA-KIDNEY/URETER^1^259
 ;;^UTILITY(U,$J,358.4,2813,0)
 ;;=KIDNEY/URETER^5^259
 ;;^UTILITY(U,$J,358.4,2814,0)
 ;;=MALIGNANT NEOPLASMS^6^259
 ;;^UTILITY(U,$J,358.4,2815,0)
 ;;=COMPLICATIONS^4^259
 ;;^UTILITY(U,$J,358.4,2816,0)
 ;;=NEURO UROLOGY^7^259
 ;;^UTILITY(U,$J,358.4,2817,0)
 ;;=BENIGN NEOPLASM-PENIS^2^259
 ;;^UTILITY(U,$J,358.4,2818,0)
 ;;=SEXUAL DISORDERS^11^259
 ;;^UTILITY(U,$J,358.4,2819,0)
 ;;=PENILE CONDITIONS^8^259
 ;;^UTILITY(U,$J,358.4,2820,0)
 ;;=POST OPERATIVE COMPLICATIONS^9^259
 ;;^UTILITY(U,$J,358.4,2821,0)
 ;;=PROSTATIC CONDITIONS^10^259
 ;;^UTILITY(U,$J,358.4,2822,0)
 ;;=TESTICULAR CONDITIONS^12^259
 ;;^UTILITY(U,$J,358.4,2823,0)
 ;;=URETHRAL CONDITIONS^13^259
 ;;^UTILITY(U,$J,358.4,2824,0)
 ;;=URINARY SYMPTOMS^14^259
 ;;^UTILITY(U,$J,358.4,2825,0)
 ;;=CEREBROVASCULAR ARTERIAL STUDIES^1^260
 ;;^UTILITY(U,$J,358.4,2826,0)
 ;;=EXTREMITY ARTERIAL-VENOUS STUDIES^3^260
 ;;^UTILITY(U,$J,358.4,2827,0)
 ;;=EXTREMITY VENOUS STUDIES^4^260
 ;;^UTILITY(U,$J,358.4,2828,0)
 ;;=VISCERAL/PENILE VASCULAR STUDIES^6^260
 ;;^UTILITY(U,$J,358.4,2829,0)
 ;;=EXTREMITY ARTERIAL STUDIES^2^260
 ;;^UTILITY(U,$J,358.4,2830,0)
 ;;=ULTRASOUNDS^5^260
 ;;^UTILITY(U,$J,358.4,2831,0)
 ;;=COMMON VASCULAR DX^1^261
 ;;^UTILITY(U,$J,358.4,2832,0)
 ;;=ABDOMINAL PAIN^2^261
 ;;^UTILITY(U,$J,358.4,2833,0)
 ;;=AFTERCARE POST SURGERY^3^261
 ;;^UTILITY(U,$J,358.4,2834,0)
 ;;=CARDIOVASCULAR^4^261
 ;;^UTILITY(U,$J,358.4,2835,0)
 ;;=METASTATIC CANCER SITES^5^261
 ;;^UTILITY(U,$J,358.4,2836,0)
 ;;=POST-OP COMPLICATIONS^6^261
 ;;^UTILITY(U,$J,358.4,2837,0)
 ;;=RESPIRATORY^8^261
 ;;^UTILITY(U,$J,358.4,2838,0)
 ;;=SIGNS & SYMPTOMS^9^261
 ;;^UTILITY(U,$J,358.4,2839,0)
 ;;=PRE-OP^7^261
 ;;^UTILITY(U,$J,358.4,2840,0)
 ;;=NEW PATIENT^2^262
 ;;^UTILITY(U,$J,358.4,2841,0)
 ;;=ESTABLISHED PATIENT^1^262
 ;;^UTILITY(U,$J,358.4,2842,0)
 ;;=CONSULTATIONS^3^262
 ;;^UTILITY(U,$J,358.4,2843,0)
 ;;=DEBRIDEMENT^1^263
 ;;^UTILITY(U,$J,358.4,2844,0)
 ;;=I&D/ASPIRATION^2^263
 ;;^UTILITY(U,$J,358.4,2845,0)
 ;;=UNNA BOOT^4^263
 ;;^UTILITY(U,$J,358.4,2846,0)
 ;;=PEG TUBE^3^263
 ;;^UTILITY(U,$J,358.4,2847,0)
 ;;=WOUND VAC DRESSING^6^263
 ;;^UTILITY(U,$J,358.4,2848,0)
 ;;=VASCULAR PROCEDURES^5^263
